EVENT SITE
WMIF MAIN SITE
7:00 AM – 8:00 AM
Grand Ballroom Foyer
7:00 AM – 5:00 PM
Grand Ballroom
Moderators
Paul Anderson, MD, PhD
Acting Chief Academic Officer, Mass General Brigham;
Professor of Medicine, HMS
Roger Kitterman
Senior Vice President, Venture, Business Development and Licensing, Mass General Brigham
Presenters
Mark Albers, MD, PhD
Frank Wilkens Jr and Family Endowed Scholar in AD Research, MGH;
Assistant Professor of Neurology, HMS
Yakeel Quiroz, PhD
Director, Familial Dementia Neuroimaging Lab and Director, Multicultural Alzheimer’s Prevention Program, MGH;
Paul B. and Sandra M. Edgerley MGH Research Scholar;
Associate Professor, HMS
Tanya Mayadas, PhD
Senior Staff Scientist, BWH;
Professor of Pathology, HMS
Synho Do, PhD
Director, Lab of Medical Imaging and Computation, Mass General Brigham;
Assistant Professor, HMS
Tatjana Jakobs, MD
Associate Scientist, Schepens Eye Research Institute of Mass Eye and Ear;
Associate Professor of Ophthalmology, HMS
Russell Jenkins, MD, PhD
Investigator, Center for Cancer Research, MGH;
Assistant Professor of Medicine, HMS
Clotilde Lagier-Tourenne, MD, PhD
Araminta Broch-Healey Endowed Chair in ALS, MGH;
Associate Professor of Neurology, HMS
Kerry Ressler, MD, PhD
Chief Scientific Officer, McLean Hospital;
Professor of Psychiatry, HMS
The Inflation Reduction Act (IRA) of 2022 will impose some of the most far-reaching changes in federal policy on biopharmaceuticals in recent years, including direct negotiation of drug prices by Medicare, and significant redesign of Medicare prescription drug benefits to lower costs borne by Medicare beneficiaries. The panel will examine the current status of key IRA provisions that may influence biopharmaceutical innovation in the years ahead, including new reporting requirements faced by industry; Medicare’s new authorities to negotiate “Maximum Fair Prices” for selected drugs; and the potential impact of lower patient costs on drug utilization.
9:30 AM – 9:45 AM
Moderators
Paul Anderson, MD, PhD
Acting Chief Academic Officer, Mass General Brigham;
Professor of Medicine, HMS
Roger Kitterman
Senior Vice President, Venture, Business Development and Licensing, Mass General Brigham
Presenters
Fabrisia Ambrosio, PhD
Atlantic Charter Director of the Discovery Center for Musculoskeletal Recovery, Schoen Adams Research Institute, Spaulding Rehabilitation Hospital;
Faculty, HMS
Li Chai, MD
Pathologist and Principal Investigator, BWH;
Associate Professor of Pathology, HMS
Angela Shen, MD
Vice President, Strategic Innovation Leaders, Mass General Brigham Innovation
Ralph Mazitschek, PhD
Principal Investigator, MGH
Assistant Professor, HMS
Shawn Demehri, MD, PhD
Director, High Risk Skin Cancer Clinic, MGH;
MGH Research Scholar;
Associate Professor, HMS
Brian Wainger, MD, PhD
Trustees Endowed Scholar in Anesthesia and Alexander Healey Endowed Chair in ALS, Neurology & Anesthesia, Critical Care and Pain Medicine, MGH;
Associate Professor, HMS
Jordan Smoller, MD, ScD
Associate Chief for Research and Director, Center for Precision Psychiatry, Department of Psychiatry, MGH;
Tepper Family MGH Research Scholar;
Professor of Psychiatry, HMS
Natalie Artzi, PhD
Associate Bioengineer, BWH;
Associate Professor of Medicine, HMS
This panel will take a focused look at the potential implications of the Inflation Reduction Act (IRA) of 2022 on biopharmaceutical innovation. While the full impact of the IRA is not yet clear, drug developers, patient advocates and other stakeholders are watching for the potential impact on small molecule drug development, on overall development of cancer therapies, on patient care for major chronic diseases, among other concerns.
Moderator
Tom Hubbard
Senior Vice President, Network for Excellence in Health Innovation (NEHI)
Panelists
Stephen Brady
CEO, Tempest Therapeutics
Remy Brim, PhD
Principal, BGR Group
Pat Fortune, PhD
Vice President, Strategic Innovation Leaders, Mass General Brigham Innovation
John Lepore, MD
SVP, Head of Research, GSK
11:15 AM – 11:30 AM
11:30 AM – 12:30 PM
11:30 AM – 12:30 PM
TBD
Moderator
Kerry Ressler, MD, PhD
Chief Scientific Officer, McLean Hospital;
Professor of Psychiatry, HMS
Panelists
Laura Germine, PhD
Co-Director of the Institute for Technology in Psychiatry,
President of the Many Brains Project, McLean Hospital;
Associate Professor of Psychiatry, HMS
Philip Wang, MD, DrPH
Director of the Center for Learning Health Systems, BWH;
Professor of the Practice of Psychiatry, HMS
Moderator
Rox Anderson, MD
Lancer Endowed Chair of Dermatology;
Director, Wellman Center for Photomedicine, MGH;
Professor of Dermatology, HMS
Panelists
Conor Evans, PhD
Principal Investigator, Wellman Center for Photomedicine, MGH;
Associate Professor, HMS
Lilit Garibyan, MD, PhD
Physician-Scientist, Wellman Center for Photomedicine, MGH;
Associate Professor of Dermatology, HMS
Moderator
Roger Kitterman
Senior Vice President, Venture, Business Development and Licensing, Mass General Brigham
Panelists
Cait Brumme
CEO, MassChallenge
Ann DeWitt, PhD
General Partner, The Engine
Johannes Fruehauf, MD, PhD
Founder & General Partner, Mission BioCapital;
Co-Founder & President, LabCentral;
CEO, BioLabs
Marc Succi, MD
Executive Director, Mass General Brigham MESH Incubator;
Associate Chair of Innovation & Commercialization, Mass General Brigham Radiology;
Strategic Innovation Leader, Mass General Brigham Innovation
Moderators
Katherine Liao, MD
Associate Physician, Department of Rheumatology, Inflammation, and Immunity, BWH;
Associate Professor of Medicine and Biomedical Informatics, HMS
Jeffrey Sparks, MD
Associate Physician, BWH;
Associate Professor of Medicine, HMS
Panelists
Nicole LeBoeuf, MD
Chief of Oncodermatology, BHW;
Vice Chair of Dermatology, Dana-Farber Brigham Cancer Center;
Associate Professor of Dermatology, HMS
Brittany Weber, MD, PhD
Director, Cardio-Rheumatology Clinic, Associate Physician, Prevention Cardiology and Cardiovascular Imaging, BWH;
Instructor of Medicine, HMS
Moderator
Adam Landman, MD
Chief Information Officer and Senior Vice President, Digital, Mass General Brigham
Associate Professor of Emergency Medicine, HMS
Panelists
Brian Anderson, MD
Chief Digital Health Physician, MITRE
Ruth Carlos, MD
Professor of Radiology, University of Michigan
Munjal Shah
Co-Founder & CEO, Hippocratic AI
Varun Singh, PhD
President & Co-Founder, Moveworks
12:30 PM – 12:45 PM
Drugs that target the brain are among the most challenging to develop, yet they also signify an area of extraordinary unmet need. Driven by a deeper understanding of the complex biology of the human brain and the emergence of validated molecular targets for neuropsychiatric and neurodegenerative diseases, the field is beginning to make important strides. This panel will discuss the innovative drugs for conditions such as ALS, Alzheimer’s disease, schizophrenia, and depression that are now in and/or emerging from the drug development pipeline.
Moderators
Maurizio Fava, MD
Chair of Psychiatry, MGH;
Slater Family Professor of Psychiatry, HMS
Greg Harrison
Vice President, Global Research, BofA Securities
Panelists
Joshua Cohen
Co-CEO, Amylyx Pharmaceuticals
Steve Davis
CEO, Acadia Pharmaceuticals
Justin Klee
Co-CEO, Amylyx Pharmaceuticals
Ivana Magovcevic-Liebisch, PhD
President & CEO, Vigil Neuroscience
Vimal Mehta, MD
CEO, BioXcel Therapeutics
3:10 PM – 3:25 PM
3:15 PM – 3:45 PM
Pavilion
Working at the intersection of multiple fields, researchers are wielding a suite of new-age tools to diagnose and treat diseases of the brain. Those include digital health tools, remote patient monitoring and telemedicine technologies, as well as novel apps and AI-based approaches. This panel will feature experts from across these varied domains to discuss the latest trends in brain health.
Moderators
Ole Isacson, MD, PhD
Director, Neuroregeneration Research Institute, McLean Hospital;
Professor of Neurology and Neuroscience, HMS
Charlie Yang, PhD
Vice President, US Biopharmaceutical Equity Research Analyst, BofA Securities
Panelists
Lisa Ricciardi
President & CEO, Cognition Therapeutics
Kasper Roet, PhD
CEO & Co-Founder, QurAlis
Robert Scannevin, PhD
Chief Scientific Officer, Verge Genomics
A new era of precision medicine is upon us and has yielded some notable successes in key disease areas. Scientists are now pursuing this vision for diseases of the brain and spinal cord, harnessing biomarkers, molecularly targeted drugs, as well as gene and cell therapies aimed at the root causes of CNS diseases. This panel will feature a discussion of the major opportunities and challenges for the field.
Moderators
Merit Cudkowicz, MD
Chair, Department of Neurology, MGH;
Julieanne Dorn Professor of Neurology, HMS
Aamir Mecklai
Managing Director, Healthcare Investment Banking, BofA Securities
Panelists
Janice Chen, PhD
Co-Founder & CTO, Mammoth Biosciences
Olivier Danos
EVP and Chief Scientific Officer, REGENXBIO
Zhen Li, PhD
President & CEO, ADARx Pharmaceuticals
Catherine Stehman-Breen, MD
CEO, Chroma Medicine
R. Nolan Townsend
CEO, LEXEO Therapeutics
5:55 PM – 6:45 PM
Pavilion
Sponsored by Siemens Healthineers
7:00 AM – 8:00 AM
Grand Ballroom Foyer
7:00 AM – 5:00 PM
Grand Ballroom Foyer
A new generation of oncology drugs is emerging that includes bispecific antibodies, antibody-drug conjugates and other novel feats of protein engineering. Together, these new biologic drugs seek to maximize tumor killing while minimizing immune and healthy tissue toxicities. The panel will discuss this new wave of innovation and what it means for the treatment of solid tumors.
9:10 AM – 9:25 AM
CAR-T cell therapy has been a game-changer for some patients with hematologic malignancies, yielding remarkable responses. Now, researchers are working to adapt and harness this technology not only to target solid tumors, but also to improve outcomes in liquid tumors. This panel will discuss the latest advances in this field — which strategies seem to hold promise, and where innovation can help move the needle for this important therapeutic modality.
By scouring the cancer genome, scientists are illuminating a suite of molecular targets and pathways that drive cancer growth and progression. These discoveries are fueling a new era of small molecule drug discovery in oncology. Hear from the leaders of key biotech companies in the field about the latest trends, opportunities, and key challenges.
10:55 AM – 11:00 AM
Grand Ballroom
The biotech sector has taken a significant downturn — and so have investments. How are these changes impacting investing patterns and habits? Will the market slump transform investment going forward or will the “old ways” return? What is the outlook for the future? Hear what leading venture capitalists are thinking about these and other topics.
Moderators
Greg Butz
Managing Director, Co-Head, North American Healthcare Investment Banking, Head of Life Sciences Investment Banking, BofA Securities
Yvonne Hao
Secretary of Economic Development, Commonwealth of Massachusetts
Sumit Mukherjee
Managing Director, Co-Head of Origination, Americas Equity Capital Markets, BofA Securities
Panelists
Jean-François Formela, MD
Partner, Atlas Venture
Craig Gordon, MD
Founder, CEO & CIO, GordonMD Global Investments
Roger Kitterman
Senior Vice President, Venture, Business Development and Licensing, Mass General Brigham
Nimish Shah
Partner, Venrock
11:50 AM – 12:50 PM
Watch Panel HereSince 2017 six CAR-T therapies have been approved by the FDA for a number of liquid tumors and these therapies have produced remarkable results for patients. In many respects these are all first generation agents and this raises the question of where does the field go next? Dual or n-plexed targeting, side effect reduction, use of different T-cell subtypes and alternative applications outside of cancer are among the possibilities. This panel of experts will discuss their view of where is this evolving field is heading.
Moderators
Noopur Raje, MD
Director, Center for Multiple Myeloma, Mass General Cancer Center;
Professor of Medicine, HMS
Alec Stranahan, PhD
Vice President, Global Research, BofA Securities
Panelists
Chip Baird
CFO, 2seventy bio
Steve Harr, MD
President & CEO, Sana Biotechnology
Laura Sepp-Lorenzino, PhD
Executive Vice President, Chief Scientific Officer, Intellia Therapeutics
Introducer
Yvonne Hao
Secretary of Economic Development, Commonwealth of Massachusetts
Moderators
Andrew Bressler
Managing Director, Global Research, BofA Securities
Adam Koppel, MD, PhD
Partner, Bain Capital Life Sciences
Panelist
Renee Wegrzyn, PhD
Director, Advanced Research Projects Agency for Health
2:35 PM – 2:50 PM
Sponsored by Canon Medical
Precision oncology, defined as molecular profiling of tumors to identify targetable alterations, is rapidly developing and has entered the mainstream of clinical practice. While the focus has been on different mutations, this panel will look at precision medicine from a different lens ranging from unique targets (ie. Menin) to harnessing different effector cells (NK-cells).
Moderators
Elisabeth Battinelli, MD, PhD
Physician, BWH;
Associate Professor, HMS
John Bishai, PhD
Managing Director, Healthcare Investment Banking, BofA Securities
Panelists
Adi Hoess, MD, PhD
CEO, Affimed
Barry Kappel, PhD
Founder, President & CEO, Sapience Therapeutics
Troy Wilson, PhD
President & CEO, Kura Oncology
For a long time, the products developed and marketed by the pharmaceutical industry consisted of small molecule drugs and natural products such as insulin. A couple of decades ago, biologics revolutionized the drug industry with the introduction of agents such as recombinant proteins and monoclonal antibodies. Today, a third arm is emerging in the form of “cells as drugs” or more concisely, cell therapy. This panel will describe some of the technological, regulatory and commercial differences implied by cell therapy adoption and some development directions that are expected to enable the greatest benefit.
Moderators
David Ting, MD
Associate Clinical Director for Innovation, Mass General Cancer Center;
Associate Professor of Medicine, HMS
Jason Zemansky, PhD
Vice President, Global Research, BofA Securities
Panelists
Tom Barnes, PhD
CEO, Orna Therapeutics
David Main
CEO, Notch Therapeutics
Andrew Schiermeier, PhD
President & CEO, AvenCell Therapeutics
4:50 PM – 5:30 PM
Grand Ballroom
Moderators
Greg Butz
Managing Director, Co-Head, North American Healthcare Investment Banking, Head of Life Sciences Investment Banking, BofA Securities
Adrian Mee
Managing Director, Head of Global Healthcare Investment Banking, BofA Securities
Panelists
Said Francis
SVP, Business Development and Corporate Strategy, Moderna
Rachna Khosla
Senior Vice President, Business Development, Amgen
Evan Lippman
Chief Corporate Development & Strategy Officer, Alnylam
5:30 PM – 6:30 PM
Pavilion
Sponsored by Canon Medical
7:00 AM – 12:00 PM
Grand Ballroom Foyer
7:00 AM – 8:00 AM
Grand Ballroom Foyer
8:00 AM – 8:25 AM
Grand Ballroom
Fireside
Focus on Inflammation and Immunology has grown massively over the past couple of decades. Initial focus was on the utilization of antibodies to block key inflammatory cytokines. Beyond cytokines, the focus shifted to also include B-cell and complement targets. More recently, the field has evolved to incorporate novel chemistry to provide patients with simple, oral solutions in a world dominated by biologics.
Scientists are developing a new generation of treatments for autoimmune and inflammatory disease that seek to restore balance to the immune system. A variety of approaches are underway, ranging from engineered immune cells, such as regulatory T cells, to re-engineered hematopoietic stem cells that rebuild patients’ blood and immune cells from the ground up. This panel will discuss these and other innovative therapies that are now under development.
Moderators
Ellen Gravallese, MD
Chief of Rheumatology, Inflammation, and Immunity, BWH;
Theodore Bevier Bayles Professor of Medicine, HMS
Alexandria Hammond, PhD
Vice President, Global Research, BofA Securities
Panelists
Diana Brainard, MD
CEO, AlloVir
Deborah Geraghty, PhD
President & CEO, Anokion
Samantha Singer
President & CEO, Abata Therapeutics
9:55 AM – 10:10 AM
Precision medicine has dominated the oncology landscape over the past several years. Now, it is time for the Immunological revolution through targeted, precision medicines. This panel will assess the various means novel companies are taking to approach this ranging from rebalancing the immune system to genomic and proteomics paired with AI.
Moderators
Vijay Kuchroo, DMV, PhD
Director, Evergrande Center for Immunologic Diseases, BWH;
Samuel L. Wasserstrom Professor of Neurology, HMS
Geoff Meacham, PhD
Managing Director, Global Research, BofA Securities
Panelist
Mikael Dolsten, MD, PhD
Chief Scientific Officer & President, Worldwide Research, Development and Medical, Pfizer
Moderators
Paul Anderson, MD, PhD
Acting Chief Academic Officer, Mass General Brigham;
Professor of Medicine, HMS
Lilit Garibyan, MD, PhD
Physician-Scientist, Wellman Center for Photomedicine, MGH;
Associate Professor of Dermatology, HMS
Rudolph Tanzi, PhD
Director, Genetics and Aging Research Unit,
Co-Director, McCance Center for Brain Health, MGH;
Joseph P. and Rose F. Kennedy Professor of Neurology, HMS
Panelists
Rachel Whooten, MD
Pediatric Endocrinologist, MGH;
Assistant Professor, HMS
Steven Arnold, MD
Director, Alzheimer’s Clinical & Translational Research Unit,
Translational Neurology Head & Managing Director, Interdisciplinary Brain Center, MGH;
Professor of Neurology, HMS
Joan Miller, MD
Chief of Ophthalmology, Mass Eye and Ear and MGH;
Ophthalmologist-in-Chief, BWH;
David Glendenning Cogan Professor of Ophthalmology, HMS
Florian Fintelmann, MD
Radiologist, Physician-Scientist, MGH;
Associate Professor of Radiology, HMS
David Ting, MD
Associate Clinical Director for Innovation, Mass General Cancer Center;
Associate Professor of Medicine, HMS
Stephanie Seminara, MD
Chief, Reproductive Endocrine Unit, MGH;
Professor of Medicine, HMS
Roger Hajjar, MD
Director, Gene & Cell Therapy Institute Mass General Brigham
Vesela Kovacheva, MD, PhD
Director of Translational and Clinical Research, BWH;
Assistant Professor of Anesthesia, HMS
James Berry, MD
Neurologist/ALS Clinical Researcher, MGH;
Associate Professor, HMS
Lindsey Baden, MD
Vice President Clinical Research, BWH;
Professor, HMS
Chadi El Saleeby, MD
Associate Pediatrician, Mass General for Children;
Assistant Professor of Pediatrics, HMS
Gerard Doherty, MD
Surgeon-in-Chief, BWH;
Moseley Professor of Surgery, HMS
12:30 PM – 12:45 PM
Grand Ballroom
© 2024 Mass General Brigham Incorporated. All Rights Reserved